Evidence map›Paper›PMID 38438737›Full record

ArticleNature medicine2024

Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

Deepak L Bhatt, Harold E Bays, Michael Miller, James E Cain, Katarzyna Wasilewska, Nabil S Andrawis, Teresa Parli, Shibao Feng, Lulu Sterling, Leo Tseng and 5 more

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Deepak L BhattMount Sinai Heart, Icahn School of Medicine, Mount Sinai Health System, New York City, NY, USA. dlbhattmd@post.harvard.edu.ORCID http://orcid.org/0000-0002-1278-6245
Harold E BaysLouisville Metabolic and Atherosclerosis Research Center, University of Louisville School of Medicine, Louisville, KY, USA.
Michael MillerCorporal Michael J. Crescenz VA Medical Center and Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
James E CainFamily Medicine Clinic Science, Lampasas, TX, USA.
Katarzyna WasilewskaZDROWIE Osteo-Medic, Bialystok, Poland.
Nabil S AndrawisManassas Clinical Research Center, Manassas, VA, USA.
Teresa Parli89bio Inc., San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9540-8436
Shibao Feng89bio Inc., San Francisco, CA, USA.
Lulu Sterling89bio Inc., San Francisco, CA, USA.
Leo Tseng89bio Inc., San Francisco, CA, USA.
Cynthia L Hartsfield89bio Inc., San Francisco, CA, USA.
Germaine D Agollah89bio Inc., San Francisco, CA, USA.
Hank Mansbach89bio Inc., San Francisco, CA, USA.
John J P KasteleinDepartment of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
ENTRIGUE Principal Investigators
Amsterdam UMC Location University of Amsterdam · NLHospital of the University of Pennsylvania · USMedical University of Białystok · PLMount Sinai Health System · USUniversity of Louisville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38438737
PMCPMC11186769
OpenAlexW4392382266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.